

TITLE OF THE INVENTION β -1.3-1.6 GLUCAN (*AUREOBASIDIUM* MEDIUM)BACKGROUND OF THE INVENTIONField of the Invention

5 The invention relates to a particular type of β -glucan--a microbial polysaccharide composed of D-glucose in either straight or branched chains with glycosidic linkages. More specifically, the present invention is directed to industrial and commercial applications of a β -1.3-1.6-glucan appearing in the medium of the black yeast, *Aureobasidium*. *Aureobasidium* is one of several genera of black yeasts, characterized by mostly slow-growing, black, pasty colonies. β -1.3-1.6-glucans are complex acidic polysaccharides having a main chain comprising subunits having 1,3 linkages and branches at the 3- and 6-positions. The β -glucans of the present invention have a variety of industrial and commercial uses, including applications in pharmaceutical or medical products or treatments, for the removal or control of environmental or microbiological contaminants, in cosmetics, and in nutritional products and foods.

Description of the Related Art

Various microbial and fungal polysaccharides with different structures and diverse physiological properties are known. Such polysaccharides have been studied from a variety of different aspects, see e.g. Hamada Nobutake: Kobunshi Kako 9-16 (1987); and Ohno Naohito: J. Bacteria Japan 527 (2000).

Microbial polysaccharides are formed from different types of monosaccharide units, such as particular types of sugars, including glucose (dextrose, grape sugar) and fructose (fruit sugar). Glucans comprise units of glucose. However, depending on the type of linkage between these subunits, a glucan may be either an α -glucan or β -glucan, see Hamada, N, Tsujisaka Y: Agric. Biol. Chem. 30: 266 (1966).

Microbial polysaccharides may have unique physical properties and physiological activities. For instance, their physical properties can provide consistency, body and

substance to foods. They can be utilized as thickening agents and as raw materials in semi-solid foods, such as jellies. Polysaccharides, such as curdlan, are utilized as antioxidant films, Szezesniak et al., J. Food Sci. 27: 381 (1962), Smiey, Food Technol 20: 112 (1966). Moreover, microbial polysaccharides which impart stability, water retention and dispensability may be used in a variety of products, including cosmetics, paints, fertilizers, papermaking, fibers, etc., Jeans, Extracellular Microbiol. Polysaccharides, Sanford et al. (eds), American Chemical Society, Washington, D.C. (1977).

On the other hand, other types of polysaccharides, such as dextran, are used for certain pharmaceutical or medical applications. For instance, dextran is utilized as a plasma substitute or blood flow improver. Polysaccharides, such as chizophyllan, scleroglucan, and curdlan have physiological activities that may be useful in treating diseases such as cancer, Komatsu et al., Gann 60: 137 (1969); Singh et al., Carbohydr. Res. 37: 245 (1974). In general, such polysaccharides do not act directly on cancer cells, but by enhancing immunity. Protein-containing polysaccharides of *Trametes versicolor* PSK, the polysaccharide lentinan of *Lentinus edodes* and the polysaccharide schizophyllan of *Schizophyllum commune* are used as immunotherapeutic drugs for cancer.

An acidic polysaccharide produced by strain FERM P-14228 is described by U.S. Patent 5,789,579. This patent is directed to α -glucans having α -1.4 bonding, unlike the β -glucans of the present invention that have β -1.3-1.6 linkages.

β -glucans are found in mushrooms, such as *Agaricus* and *Lentinus*, various starches, cellulose, seaweeds, red algae, yeasts and other similar micro-organisms. Some types of β -glucans play a significant role in health maintenance, see Fujii Noboru: A miracle of β -glucan, Society for Study of Beta Glucan. The present inventors have found that β -1.3-1.6glucan (*Aureobasidium medium*) contains much higher quantities of β -glucan than mushrooms--over ten-times more.

Physiological Effects of β -glucans. Many studies have been made with respect to the physiological effects of β -glucans. In particular, the regulatory actions of these compounds on the vital balance and vital immune reaction have been studied. For instance, the protective effects of these compounds in cancer and infectious disease have been studied. Some types of β -glucans, which are of a different type from those of the present invention,

have antitumor activities. For instance, these have been observed on 3LL solid tumor cells derived with methylcholanthrene-I in experimental animals, see Fujii Noboru, Shinohara Satoru: Report of the Department of Agriculture, Miyazaki University 33: 243 (1986).

Glucan Receptor. β -glucan receptors are known to be expressed on immunocompetent cells, such as monocytes and macrophages, see Czop et al., J. Exp Med 173: 1511 (1991), Xia et al., J. Immunol. 162: 7285 (1999), Czop, et al., Prog. Clin. Biol. Res. 297: 287 (1989). Certain β -glucans are known to induce the production of inflammatory cytokines from immunocompetent cells, for example, the interleukin 1 receptor antagonist (IL-1Ra) which is an antagonist of interleukin 1 β (IL-1 β), see Poutsiake et al., Blood 82: 3695 (1993). It also induces the production of tumor necrosis factor- α (TNF- α), interleukin 1 β (IL-1 β) and platelet activating factor (PAF), and the like, see Abel et al., Int. J. Immunopharmacol. 14: 1363 (1992), Elstad, et al., J. Immunol. 52: 220 (1994).

The molecular structure of the β -glucan receptor has been found to correspond to complement receptor 3 ("CR3") that binds complement component C3. Recently, this receptor has been shown to be an integrin type CD11b/CD18 molecule itself, see Ress, et al., Complement 4: 61 (1987), Thornton, et al., J. Immunol. 156: 235 (1996). It has also been found that this CR3 (CD11b/CD18) molecule is a receptor mainly manifested on the cell surface of monocytes and macrophages and in NK cells. NK cells activated by β -glucan bonding to the CD11b/CD18 molecule via this receptor (CR3) molecule are involved in the destruction and removal of cancer cells, see Di Renzo et al., Eur. J. Immunol. 21: 1755 (1991), Ross, et al., Immunopharmacology 42: 61 (1999), Yan, et al., J. Immunol. 163: 3045 (1999).

Signal transmission. The analysis of signal transmission modes from the β -glucan receptor has been studied. $\text{Nf-}\kappa\text{B}$ plays a role as an intranuclear transmission substance of immuno-B-cyte which takes part closely in this signal transmission system, Wakshull et al., Immunopharmacology 41: 89 (1999). Moreover, in model experiments for the therapy of cancer, from the fact that β -glucan is a receptor (CD11b/CD18 molecule) of C3 component of complement, see Yan, et al., J Immunol 163: 3045 (1999), it is reported that the route via this receptor is effective for the destruction of cancer cells opsonized with specific antibody of cancer, see Xia et al., J. Immunol. 162: 2281 (1999).

Drug effects on glucan receptor. On the other hand, functional experiments between drugs having an influence on the immune reaction and β -glucan receptor are also being conducted, and new roles of β -glucan in the vital immune system have become clear in such ways that, in particular, β -glucan receptor (CD11b/CD18 molecule) accelerates its receptor function with glucocorticoid, and the like, see Yashioka et al., FEMS Immunol. Med. Microbiol. 21: 171 (1998), Kay, et al., Immunology 81: 96 (1994).

Glucan effects *in vivo*. The effects of β -glucans *in vivo* have also been investigated. Administration of a glucan increases the survival and longevity (macrobiotic effect) of mice exposed to lethal levels of radiation. This effect is attributed to hemopoietic effects of β -glucan and direction of immunocompetent cells into a maturation process, see Patchen et al., Methods Find. Exp. Clin. Pharmacol. 8: 151 (1986). In addition, β -glucans stimulate macrophage function and may thus provide protective effects against certain infectious diseases, such as tuberculosis, see Hetland et al., Scand. J. Immunol 47: 548 (1998). Immunization with the glucan-binding domain of *Streptococcus mutans* glucosyltransferase provides immunity against infection with *Streptococcus mutans*, see Jespersgaard et al., Infect. Immun. 67: 6543 (1999).

Immune enhancement with glucans and other substances. While some β -glucans may enhance certain components of the immune system, such as macrophage function, immunological enhancement is a complex phenomenon and at the cell level many intracellular transmission substances are involved in producing these effects. For instance, recently it has been found that mitogen activating protein kinase (MAPK) and calcium controlling the activation and management of immune system are closely involved in these phenomena, see McLeish, et al., J. Leukoc. Biol. 64: 835 (1998), Mork, et al., Immunopharmacology 40: 77 (1998).

β -glucan analogs and diagnosis. Clinically, β -glucan analogues in plasma in patients with pneumonia have been observed. For instance, β -glucan analogues increase in plasma in cases of *Pneumocystis carinii* pneumonia having no overt AIDS-like symptoms, see Teramoto et al., J. Med. Microbiol. 49: 393 (2000).

While some β -glucans were known to stimulate particular components of the cellular immune system, such as macrophage functions, the present inventors have found that the β -1.3-1.6glucan (*Aureobasidium* medium) of the present invention exerts other specific

functional activities, such as inducing increases in the numbers of lymphocytes, inducing DNA synthesis and cell division in lymphocytes, exerting direct effects on cancer cells, and directly inhibiting the proliferation of microbes.

SUMMARY OF THE INVENTION

5 The invention relates to an *Aureobasidium* medium containing β -1.3-1.6glucan as a major component and a method of producing the same by culturing fungi that produce β -1.3-1.6glucan of *Aureobasidium*. The unique functional properties of the β -glucans of the present invention, which include particular modulatory and regulatory effects on the immune system, make these products particularly advantageous for a variety of industrial and commercial applications. The glucans of the present invention may be used as present in *Aureobasidium* culture medium, which is preferably sterilized or filtered, or may be used after further purification. Such applications include use in pharmaceutical or medical products or treatments, in diagnostic products and methods, for the removal or control of environmental or microbiological contaminants, in chemical products, in cosmetics, and in nutritional products and foods.

10 The present inventors have discovered that β -1.3-1.6glucan (*Aureobasidium* medium) prepared according to the invention has unique physical properties and physiological activity quite different from those of other types of β -glucans. In particular, the β -1.3-1.6glucan (*Aureobasidium* medium) of the present invention modulates and regulates the immune system. It has been found to have a specific effect on the production of interleukin-6 (IL-6) which is involved in controlling the number of lymphocytes in human peripheral blood, in cell division and in other aspects of immunity.

15 Moreover, the β -1.3-1.6glucan (*Aureobasidium* medium) of the present invention effectively inhibited the proliferation of cancer cells, such as leukemia cells. While not being limited to a particular mechanism of action, it is considered that this effect may involve the programmed death of cancer (leukemia) cells or apoptosis. Thus, the β -1.3-1.6glucan (*Aureobasidium* medium) of the present invention has advantageous applications for clinical therapy of cancer.

20 It has also been found that β -1.3-1.6glucan (*Aureobasidium* medium) influences the

expression or function of adhesion molecules involved in immunity. For instance, the inhibition of expression or down-regulation of integrin-type adhesion molecules, such as CD11a and CD49d, expressed in monocytic cells was recognized. This finding provides for application of β -1.3-1.6glucan (*Aureobasidium* medium) in the treatment of various microbial diseases. For instance, the CD11a molecule is a receptor for rotavirus, which causes infant and child diarrhea. Since β -1.3-1.6glucan (*Aureobasidium* medium) down-regulates the expression or function of CD11a molecules as shown in the example below, it may be used to prevent the attachment or adsorption of rotavirus, and prevent or ameliorate infections involving CD11a.

Moreover, the CD49d molecule is also an integrin type adhesion molecule and an immune function regulator. This molecule is considered to be strongly involved in the infiltration of T lymphocytes into the articular synovial membrane of patients having chronic articular rheumatism. Since the expression of CD49d molecule is also subject to the down-regulation with β -1.3-1.6glucan (*Aureobasidium* medium), it may be used in methods for therapy of diseases such as chronic articular rheumatism and other autoimmune diseases, involving expression of CD49d. Thus, the β -1.3-1.6glucan (*Aureobasidium* medium) may exert anti-inflammatory effects.

Applicants have also discovered that apart from the advantageous immunological effects of β -1.3-1.6glucan (*Aureobasidium* medium), that this substance may be used for preventing the propagation of environmental microbes. Thus, β -1.3-1.6glucan (*Aureobasidium* medium) may be used as a novel antiseptic, preservative or antimicrobial agent. Such agents have application for maintaining personal cleanliness, for instance of the body, hands or feet, and as a portable disinfectant. Such a disinfectant may be used for persons who cannot bathe, such as the aged or infirm and for prevention of nosocomial infections. It may also be used to remove environmental pollutants.

As described and shown below, the present invention involving β -1.3-1.6glucan (*Aureobasidium* medium) may be advantageously and safely used in medical and pharmaceutical products and methods, in foods and cosmetics and as an antiseptic or antimicrobial agent.

BRIEF DESCRIPTION OF THE DRAWINGS

Fig. 1 shows the influence of β -1.3-1.6glucan (*Aureobasidium* medium) on the numbers of lymphocytes in peripheral blood.

Fig. 2, panels (a) and (b) compare the morphological changes in lymphocytes grown in control medium with those grown in medium containing β -1.3-1.6glucan (*Aureobasidium* medium).

Fig. 3 shows the influence of β -1.3-1.6glucan (*Aureobasidium* medium) on the proliferation of U937 leukemia cells.

Fig. 4 shows the influence of β -1.3-1.6glucan (*Aureobasidium* medium) on the proliferation of Molt-4 leukemia cells.

Fig. 5 shows the influence of β -1.3-1.6glucan on the proliferation of P30/OHK leukemia cells.

Fig. 6 shows the influence of β -1.3-1.6glucan (*Aureobasidium* medium) on the proliferation of Raji leukemia cells.

Fig. 7, panels (a) and (b) show the influence of β -1.3-1.6glucan (*Aureobasidium* medium) on cell surface molecules CD11a and CD49d, respectively.

Fig. 8, panels (a) and (b) show palm stamps of untreated hands and hands wiped with β -1.3-1.6glucan (*Aureobasidium* medium), respectively. Black marks depict the growth of microorganisms.

DETAILED DESCRIPTION OF THE INVENTION

Aureobasidium medium that contains β -1.3- 1.6glucan may be produced by strains of *Aureobasidium*. Advantageously, strain FERM P-18099 may be used. This strain has been deposited at the:

The characteristics of this strain are described below.

5 Properties, taxonomy and mycological features of FERM P-18099. FERM P-18099 is a black fungus used for preparing *Aureobasidium* medium that contains β -1,3- 1,6glucan as a major component. Its properties are as follows:

10 Scientific properties. This fungus produces high-molecular polysaccharide with high viscosity. This substance agglutinates easily with ethanol, making it possible to collect simply. Other purification methods, such as those described by U.S. Patent 5,789,579 for purification of an α -type acid polysaccharide, may also be used. This polysaccharide is of β type, and is acidic polysaccharide having a main chain of 1,3 bond and branches from 3- and 6-positions. It contains carboxylic acids such as malic acid as organic acids and phosphoric acid. Moreover, it agglutinates easily with aluminum ions etc. This substance is also effective for the promotion of growth as a feed and the effluent treatment. It is effective as a food additive and functional food with immunity.

15 Taxonomic position. FERM P-18099 forms blackish brown colonies on potato-dextrose-agar slant culturing for 7 days at 25 C. The fringe of colonies shows filamentous growth and becomes gradually light blackish brown. The cells are filamentous, 20 and sometimes arthrospores, yeast-like budding conidiospores, oval yeast-like single cells, and, in some time, thick-walled spore cells are formed. The growth temperature is 25°C, and it decomposes hexoses such as glucose, fructose and galactose, sucrose, and starch. The medium becomes conspicuously viscous. Based on FERM P-18099's mycological properties, it is a kind of *Aureobasidium pullulans* in the black fungus family of deuteromycetes.

25 Mycological features of the isolated fungus. A colony of FERM P-18099 has a smooth surface at first and grows into a grayish white, mucous and glossy oil drop-like (fat-like), yeast-like material. The filamentous fungus body grows radially from the fringe thereof, leading to crinkled, filamentous and just dendritic growth. This filamentous fungus body grows well not only on the surface of medium, but also in the medium. In a short time, 30 light dark brown specks appear here and there on the surface of colony, which become black

specks gradually, and overall surface becomes dark black eventually. On this filamentous fungus body, a lot of light brown, elliptic or oval conidiospores are produced laterally. This conidiospore falls easily in pieces. While the surface of oil drop-like colony puts on the conidiospores here and there.

- 5 A medium containing sugars becomes very viscous and produces leather-like black culture moss on the surface of medium with thick colony formation. The optimum growth temperature is 20 to 25° C, and it yields alcohols and organic acids from sugars such as grape sugar and cane sugar. It gives out peculiar fragrance.

Cultural features. *Aureobasidium* may be cultured on solid or liquid media.

- 10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000
1001
1002
1003
1004
1005
1006
1007
1008
1009
1010
1011
1012
1013
1014
1015
1016
1017
1018
1019
1020
1021
1022
1023
1024
1025
1026
1027
1028
1029
1030
1031
1032
1033
1034
1035
1036
1037
1038
1039
1040
1041
1042
1043
1044
1045
1046
1047
1048
1049
1050
1051
1052
1053
1054
1055
1056
1057
1058
1059
1060
1061
1062
1063
1064
1065
1066
1067
1068
1069
1070
1071
1072
1073
1074
1075
1076
1077
1078
1079
1080
1081
1082
1083
1084
1085
1086
1087
1088
1089
1090
1091
1092
1093
1094
1095
1096
1097
1098
1099
1100
1101
1102
1103
1104
1105
1106
1107
1108
1109
1110
1111
1112
1113
1114
1115
1116
1117
1118
1119
1120
1121
1122
1123
1124
1125
1126
1127
1128
1129
1130
1131
1132
1133
1134
1135
1136
1137
1138
1139
1140
1141
1142
1143
1144
1145
1146
1147
1148
1149
1150
1151
1152
1153
1154
1155
1156
1157
1158
1159
1160
1161
1162
1163
1164
1165
1166
1167
1168
1169
1170
1171
1172
1173
1174
1175
1176
1177
1178
1179
1180
1181
1182
1183
1184
1185
1186
1187
1188
1189
1190
1191
1192
1193
1194
1195
1196
1197
1198
1199
1200
1201
1202
1203
1204
1205
1206
1207
1208
1209
1210
1211
1212
1213
1214
1215
1216
1217
1218
1219
1220
1221
1222
1223
1224
1225
1226
1227
1228
1229
1230
1231
1232
1233
1234
1235
1236
1237
1238
1239
1240
1241
1242
1243
1244
1245
1246
1247
1248
1249
1250
1251
1252
1253
1254
1255
1256
1257
1258
1259
1260
1261
1262
1263
1264
1265
1266
1267
1268
1269
1270
1271
1272
1273
1274
1275
1276
1277
1278
1279
1280
1281
1282
1283
1284
1285
1286
1287
1288
1289
1290
1291
1292
1293
1294
1295
1296
1297
1298
1299
1300
1301
1302
1303
1304
1305
1306
1307
1308
1309
1310
1311
1312
1313
1314
1315
1316
1317
1318
1319
1320
1321
1322
1323
1324
1325
1326
1327
1328
1329
1330
1331
1332
1333
1334
1335
1336
1337
1338
1339
1340
1341
1342
1343
1344
1345
1346
1347
1348
1349
1350
1351
1352
1353
1354
1355
1356
1357
1358
1359
1360
1361
1362
1363
1364
1365
1366
1367
1368
1369
1370
1371
1372
1373
1374
1375
1376
1377
1378
1379
1380
1381
1382
1383
1384
1385
1386
1387
1388
1389
1390
1391
1392
1393
1394
1395
1396
1397
1398
1399
1400
1401
1402
1403
1404
1405
1406
1407
1408
1409
1410
1411
1412
1413
1414
1415
1416
1417
1418
1419
1420
1421
1422
1423
1424
1425
1426
1427
1428
1429
1430
1431
1432
1433
1434
1435
1436
1437
1438
1439
1440
1441
1442
1443
1444
1445
1446
1447
1448
1449
1450
1451
1452
1453
1454
1455
1456
1457
1458
1459
1460
1461
1462
1463
1464
1465
1466
1467
1468
1469
1470
1471
1472
1473
1474
1475
1476
1477
1478
1479
1480
1481
1482
1483
1484
1485
1486
1487
1488
1489
1490
1491
1492
1493
1494
1495
1496
1497
1498
1499
1500
1501
1502
1503
1504
1505
1506
1507
1508
1509
1510
1511
1512
1513
1514
1515
1516
1517
1518
1519
1520
1521
1522
1523
1524
1525
1526
1527
1528
1529
1530
1531
1532
1533
1534
1535
1536
1537
1538
1539
1540
1541
1542
1543
1544
1545
1546
1547
1548
1549
1550
1551
1552
1553
1554
1555
1556
1557
1558
1559
1560
1561
1562
1563
1564
1565
1566
1567
1568
1569
1570
1571
1572
1573
1574
1575
1576
1577
1578
1579
1580
1581
1582
1583
1584
1585
1586
1587
1588
1589
1590
1591
1592
1593
1594
1595
1596
1597
1598
1599
1600
1601
1602
1603
1604
1605
1606
1607
1608
1609
1610
1611
1612
1613
1614
1615
1616
1617
1618
1619
1620
1621
1622
1623
1624
1625
1626
1627
1628
1629
1630
1631
1632
1633
1634
1635
1636
1637
1638
1639
1640
1641
1642
1643
1644
1645
1646
1647
1648
1649
1650
1651
1652
1653
1654
1655
1656
1657
1658
1659
1660
1661
1662
1663
1664
1665
1666
1667
1668
1669
1670
1671
1672
1673
1674
1675
1676
1677
1678
1679
1680
1681
1682
1683
1684
1685
1686
1687
1688
1689
1690
1691
1692
1693
1694
1695
1696
1697
1698
1699
1700
1701
1702
1703
1704
1705
1706
1707
1708
1709
1710
1711
1712
1713
1714
1715
1716
1717
1718
1719
1720
1721
1722
1723
1724
1725
1726
1727
1728
1729
1730
1731
1732
1733
1734
1735
1736
1737
1738
1739
1740
1741
1742
1743
1744
1745
1746
1747
1748
1749
1750
1751
1752
1753
1754
1755
1756
1757
1758
1759
1760
1761
1762
1763
1764
1765
1766
1767
1768
1769
1770
1771
1772
1773
1774
1775
1776
1777
1778
1779
1780
1781
1782
1783
1784
1785
1786
1787
1788
1789
1790
1791
1792
1793
1794
1795
1796
1797
1798
1799
1800
1801
1802
1803
1804
1805
1806
1807
1808
1809
1810
1811
1812
1813
1814
1815
1816
1817
1818
1819
1820
1821
1822
1823
1824
1825
1826
1827
1828
1829
1830
1831
1832
1833
1834
1835
1836
1837
1838
1839
1840
1841
1842
1843
1844
1845
1846
1847
1848
1849
1850
1851
1852
1853
1854
1855
1856
1857
1858
1859
1860
1861
1862
1863
1864
1865
1866
1867
1868
1869
1870
1871
1872
1873
1874
1875
1876
1877
1878
1879
1880
1881
1882
1883
1884
1885
1886
1887
1888
1889
1890
1891
1892
1893
1894
1895
1896
1897
1898
1899
1900
1901
1902
1903
1904
1905
1906
1907
1908
1909
1910
1911
1912
1913
1914
1915
1916
1917
1918
1919
1920
1921
1922
1923
1924
1925
1926
1927
1928
1929
1930
1931
1932
1933
1934
1935
1936
1937
1938
1939
1940
1941
1942
1943
1944
1945
1946
1947
1948
1949
1950
1951
1952
1953
1954
1955
1956
1957
1958
1959
1960
1961
1962
1963
1964
1965
1966
1967
1968
1969
1970
1971
1972
1973
1974
1975
1976
1977
1978
1979
1980
1981
1982
1983
1984
1985
1986
1987
1988
1989
1990
1991
1992
1993
1994
1995
1996
1997
1998
1999
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
2032
2033
2034
2035
2036
2037
2038
2039
2040
2041
2042
2043
2044
2045
2046
2047
2048
2049
2050
2051
2052
2053
2054
2055
2056
2057
2058
2059
2060
2061
2062
2063
2064
2065
2066
2067
2068
2069
2070
2071
2072
2073
2074
2075
2076
2077
2078
2079
2080
2081
2082
2083
2084
2085
2086
2087
2088
2089
2090
2091
2092
2093
2094
2095
2096
2097
2098
2099
2100
2101
2102
2103
2104
2105
2106
2107
2108
2109
2110
2111
2112
2113
2114
2115
2116
2117
2118
2119
2120
2121
2122
2123
2124
2125
2126
2127
2128
2129
2130
2131
2132
2133
2134
2135
2136
2137
2138
2139
2140
2141
2142
2143
2144
2145
2146
2147
2148
2149
2150
2151
2152
2153
2154
2155
2156
2157
2158
2159
2160
2161
2162
2163
2164
2165
2166
2167
2168
2169
2170
2171
2172
2173
2174
2175
2176
2177
2178
2179
2180
2181
2182
2183
2184
2185
2186
2187
2188
2189
2190
2191
2192
2193
2194
2195
2196
2197
2198
2199
2200
2201
2202
2203
2204
2205

Morphological features. Young cells are transparent, filamentous, crinkled and dendritic. Black oval spore-like fungus bodies (filamentous) are produced laterally in places. Adherent black spore-like oil drop-like colonies are found. These structures are frangible and fall into pieces when given a shock.

5 Physiological features. The optimum growth temperature is 20 to 25°C. The culture yields viscous material from carbon sources such as, glucose, sucrose, etc. and alcohols and organic acids from sugars such as glucose. It gives out peculiar fragrance.

Method for making β -1.3-1.6glucan (*Aureobasidium* medium)

10 Based on the above information, the β -1.3-1.6glucan (*Aureobasidium* medium) to be used in the invention is β -glucan produced by the latest cultural technology, to which we added additional developments and improvements. *Aureobasidium* medium containing β -1.3-1.6glucan may be produced by culturing *Aureobasidium* in a solid or preferably a liquid culture medium supporting its growth. Such culture media include a carbon source, such as a sugar or carbohydrate, a nitrogen source, such as amino acids or a peptide mixture, and other nutrients, such as salts of sodium, potassium, phosphorous, iron, manganese, magnesium, calcium and sulfur. As mentioned above, culture media include potato-glucose medium and Czapek medium. Other culture conditions, such as those described in U.S. Patent 5,789,579 for culture of a strain producing an α -type acidic polysaccharide, may also be used.

20 A liquid culture is preferably agitated or aerated. The pH of the culture may range from 2 to 10 and the culture temperature preferably ranges from about 20 to 25° C. *Aureobasidium* medium containing β -1.3-1.6glucan may be harvested after 1 to 10 days, preferably at the point of maximal production of β -1.3-1.6glucan. Medium may be separated from cells by centrifugation, for instance, by an initial low speed centrifugation at 5,000 rpm and a high-speed centrifugation at 12,000 rpm. Preferably, the β -1.3-1.6glucan level in *Aureobasidium* medium is at least 10 times higher than B-glucan levels found in mushrooms. Culture medium may be used directly, after sterilization or filtration, or after further purification.

25 β -1.3-1.6glucan in β -1.3-1.6glucan in *Aureobasidium* medium may be further purified
30 by agglutination with an organic solvent, such as ethanol, or by agglutination with metal ions,

such as aluminum ions. Of course, other convention purification methods may used to further purify the β -1.3-1.6glucan in *Aureobasidium* medium, including precipitation, filtration, chromatography and electrophoresis. Preferably, the β -1.3-1.6glucan is sterilized by convention methods, for instance, by heat treatment or filtration, prior to use.

5 While β -glucans may also be extracted from the cell walls of *Aureobasidium*, such cell wall extracts may lose their functional properties upon extraction and fractionation.

The β -1.3-1.6glucan (*Aureobasidium* medium) of the present invention exhibit unique physical and physiological properties different from other β -glucans produced by other types of fungi, making it particularly useful in commercial and industrial applications, especially in
10 the fields of medical care, health and welfare and in the food industry. The present inventors have found that β -1.3-1.6glucan (*Aureobasidium* medium) produced with black yeast (*Aureobasidium*) exerts particular regulatory and modulatory effects on the immune system. For instance, β -1.3-1.6glucan (*Aureobasidium* medium) may be used to increase the numbers of lymphocytes. It may also be used to promote DNA synthesis (cell division), change the morphology of monocytic cells, and modify functional molecules, such as receptors, on the surface of cell membrane. β -1.3-1.6glucan (*Aureobasidium* medium) also reduces the proliferation of cancer cells and thus exerts an anticancer effect. Moreover, it has also been found that the β -1.3-1.6glucan (*Aureobasidium* medium) inhibits the proliferation of microbes, such as microbes which adhere to skin surfaces like the hands and feet. Thus, it
20 exerts an antimicrobial and infection-preventative effect.

β -1.3-1.6glucan (*Aureobasidium* medium) may be used in method for treating inflammatory, infectious or neoplastic diseases. These disease include, for instance, chronic articular rheumatism, collagen disease, newly-risen autoimmune disease, virus or bacterial infection, cancer, invasive or metastatic cancer, oncogenic virus, neuropathy, dementia,
25 Alzheimer's disease, hepatic disease, cirrhosis, viral hepatic disease, cryptogenic intractable disease, life habit disease, diabetes, hypertension, arterial sclerosis, osteoporosis, hemorrhoids, or radiation damage. β -1.3-1.6glucan (*Aureobasidium* medium) may be administered by topically, orally, by application to a mucous membrane, by inhalation, or by parenteral, subcutaneous or intravenous administration. β -1.3-1.6glucan (*Aureobasidium*
30 medium) may be formulated into an appropriate form, such as into a sterile or lyophilized form, for such modes of administration or into unit dosages. It may also optionally be

combined with other pharmaceutical products or drugs.

β -1.3-1.6glucan (*Aureobasidium* medium) may be used in food products.

Advantageously, the beneficial immunological and antimicrobial characteristics of this product may be useful for addition to foods for debilitated or immunocompromised patients, such as aseptic or germless foods for debilitated or immunocompromised patients, such as transplantation patients. For instance, it may be used in foods administered to patients in sterilized rooms after bone marrow transplantation or for burn victims. It may also be used in health foods or nutritional supplements for health maintenance and promotion. It may be used in foods for the aged or debilitated, such as patients who need to maintain their physical strength and disease resistance, or for persons with digestion or assimilation problems, such as deglutition disorders. It may also be used during other types of rehabilitation procedures, or for pregnant women or women under climacteric disturbance (such as menopause).

β -1.3-1.6glucan (*Aureobasidium* medium) may also be incorporated into health foods to maintain a subject's physiological or immunological vitality and balance.

The type of food product into which β -1.3-1.6glucan (*Aureobasidium* medium) may be applied or incorporated is not particularly limited and may include liquid, semisolid or solid food products. For instance, the β -1.3-1.6glucan (*Aureobasidium* medium) may be added to hot or cold drinks, including soft drinks, milk products, soy or rice milk products, fruit or vegetable juices; fermented milk products, such as cheeses and yoghurt; ice cream or other frozen products, gelatin or agar products; canned or preserved products, such as jams or jellies, condiments, including catsup, mustards, sauces or gravies, and relishes; canned meats, fruits or vegetables; cereal products, such as rice or wheat products, including noodles, pastas, breads and crackers and cookies. The β -1.3-1.6glucan (*Aureobasidium* medium) may also be formulated into special nutritional foods, such as hospital foods or nutritional formulas, or as into a nutritional supplement, for instance, into tablet or capsule, optional in combination with other nutrients, such as vitamins or minerals. Such capsules, tablets or pills, advantageously contain between 1 mg and 1,000 mg of β -1.3-1.6glucan (*Aureobasidium* medium). Solutions of the β -1.3-1.6glucan (*Aureobasidium* medium) of the present invention may also be applied or sprayed on the surfaces of foods, such as fresh fruits and vegetables to prevent or inhibit microbial contamination or spoilage.

The β -1.3-1.6glucan (*Aureobasidium* medium) may also be incorporated into personal

care products, such as toothpastes or mouthwash, or into a cosmetic, such as shampoo, soap, powder, such as a body or face powder, a gel, a film, a masque, a cosmetic cream, or a lotion. Such compositions and products may also be used to treat topical skin disorders, infections, or burns, including sunburns or UV irradiation, or to protect the connective skin tissue.

5 Products, including pharmaceutical, food, personal care and cosmetic products, contain about 0.001mg/ gr to 100mg/gr of β -1.3-1.6glucan from *Aureobasidium* (culture medium) and a preferable amount of *Aureobasidium* culture medium to be used in such products and compositions is from 0.1 to 100 parts by weight%. *Aureobasidium* culture medium preferably contains from about 3 to 5 mg/ml β -1.3-1.6glucan. Accordingly, such
10 products may also preferably contain from about .003 to 5 mg/ml β -1.3-1.6glucan. Foods preferably contain about 5 to 100 parts by weight/100 parts total weight of *Aureobasidium* culture medium.

β -1.3-1.6glucan (*Aureobasidium* medium) may be formulated into a pharmaceutical product, such as a product for modulating the immune system, or for treating a microbial or inflammatory disease. The β -1.3-1.6glucan (*Aureobasidium* medium) may be ingested, applied topically or parenterally, or administered directly to the site or biological compartment containing cancer cells. It may also be incorporated into a diagnostic product, as an auxiliary reagent (e.g. a buffer, stabilizer or preservative), or as an active component for the diagnosis of diseases associated with altered levels of glucans.

20 Moreover, as shown below, β -1.3-1.6glucan (*Aureobasidium* medium) may be used in products and compositions for the prevention of nosocomial infection or removal of environmental pollutants, for instance, into agents that prevent the propagation of microbes. It may also be used as a sanitizer or disinfectant, for instance, for cleaning the bodies of persons who are aged or infirm and cannot bathe. The *Aureobasidium* culture medium may
25 also be used undiluted as a disinfectant. Additionally, it may be used to treat hospital personnel, patients, surfaces, equipment, supplies or instruments in order to prevent nosocomial infections. Moreover, it may be used to remove environmental pollutants, such as internal secretion detractors, environmental hormones, toxins, heavy metals, and dioxins. As a sanitizer or disinfectant, β -1.3-1.6glucan (*Aureobasidium* medium) may be added to
30 water or other conventional cleaning or disinfectant solutions, including detergent or soap solutions.

EXAMPLES

The following examples illustrate the effects of β -1.3-1.6glucan (*Aureobasidium* medium) on the immune system.

To test these effects, peripheral lymphocytes were conventionally separated from peripheral blood of normal and healthy subjects. Separated lymphocytes were divided into control groups, which were not treated with β -1.3-1.6glucan (*Aureobasidium* medium) and into experimental groups treated with β -1.3-1.6glucan (*Aureobasidium* medium).

Control and experimental groups were cultured in an appropriate culture medium (RPMI 1640 containing 10% fetal calf serum (FCS) and 20% human serum (HS)) for a fixed period to investigate the influence of β -1.3-1.6glucan (*Aureobasidium* medium) on the numbers of lymphocytes, cell division of lymphocytes, production level of IgG antibody and on the production of cytokines. Moreover, morphological change of the peripheral blood lymphocytes was observed using a phase microscope. Moreover, the effects of β -1.3-1.6glucan (*Aureobasidium* medium) treatment on lymphocytic cell surface molecules (receptors) was determined.

Additionally, the effects of β -1.3-1.6glucan (*Aureobasidium* medium) on different types of cancer cells, such as different leukemia cell lines, were determined by comparison of control cancer cells receiving no treatment with β -1.3-1.6glucan (*Aureobasidium* medium), with experimental samples of the same types of cancer cells treated with β -1.3-1.6glucan (*Aureobasidium* medium). The number of lymphocytes was observed and calculated under phase microscope by using hemocytometer. See Fig. 1.

The capacity of control or treated lymphocytes to synthesize DNA was determined by a convention method. Namely, it was measured by the uptake or incorporation of tritiated thymidine (3H-thymidine) as measured by scintillation counting. Uptake is represented by the number of counts per minute, cpm. See Tables 4 and 5.

The production level of antibody from the lymphocytes in human peripheral blood with β -1.3-1.6glucan (*Aureobasidium* medium), that is, the production level of IgG antibody from B cells being immunocytes was determined by using enzyme antibody technique. Namely, according to the usual method, the amount of antibody in actual medium was determined by using double antibody enzyme antibody, enzyme immunoassay (EIA)

technique. There are many methods for determining the amount of antibody, for example, method using plaque technique, Ouchterlony technique, fluorescent antibody technique, etc. However, the EIA technique used in the examples has very high sensitivity and allows to determine even with small amount of material, hence it is a method used routinely as an immunological examination technique. See Table I which shows effects of β -1.3-1.6glucan (*Aureobasidium* medium) on IgG production.

For investigating the influence of β -1.3-1.6glucan (*Aureobasidium* medium) on lymphocytes, the production levels of particular cytokines, such as interleukin and interferon, was determined by an enzyme-antibody technique. The enzyme-antibody technique measures the amounts of serum and cytokines in medium. Commercial kits for this technique are available from various firms. The levels of cytokines, such as interleukin 1, 2, 4, 6, and interferon were determined using this method. Evaluation of the effects of β -1.3-1.6glucan (*Aureobasidium* medium) on particular aspects of the immune system was done by a determination of the amounts of and dynamics of cytokine production or release. These results are presented in Tables II and III.

For investigating the morphological changes of lymphocytes treated with β -1.3-1.6glucan (*Aureobasidium* medium), the lymphocytes cultured with β -1.3-1.6glucan (*Aureobasidium* medium) are observed under phase microscope. Following this, their morphological change, in particular, shape of cells and change in the ruffle structure of cell surface are observed and taken into photographs. See Fig. 2.

With respect to the investigation on the change in dynamics of lymphocyte or surface molecule (receptor) of model cell cultured with β -1.3-1.6glucan (*Aureobasidium* medium), the flow cytophotometry technique (fluorescence activated cell sorter: FACS) is used. This advantageous method is capable of analyzing the dynamics of cell surface antigen and receptor as an immunologically analyzing means. This determination is conducted by using monoclonal antibody that reacts specifically with cell surface and antibody labeled with fluorescence, and, actually, the fluorescence intensity is image analyzed with computer after the reflection of laser beam was taken-in, and the results are converted to histogram. See Fig. 7.

The influence of β -1.3-1.6glucan (*Aureobasidium* medium) on the proliferation of

cancer cells, in particular, leukemia cells is judged by the life and death of cancer cells cultured with β -1.3-1.6glucan (*Aureobasidium* medium) for a fixed period. Namely, according to this method, the leukemia cells cultured with β -1.3-1.6glucan (*Aureobasidium* medium) are collected and the life and death of cancer cells are counted by using hemocytometer to investigate the extent of proliferation of cancer cells. In some experiments, cells are stained actually by using stain solution to investigate the influence of β -1.3-1.6glucan (*Aureobasidium* medium) on the extent of proliferation of cancer cells. See Figs. 3-6.

For investigating the effect of β -1.3-1.6glucan (*Aureobasidium* medium) on the removal of environmental microbes, a palm stamp on a conventional agar medium was used. This method counts the number of microbial colonies on the palm stamp on the agar medium as a measure of number of environmental microbes adhered to the skin surface. Conventional tryptosoy agar medium (medium: trypton, soy peptone, sodium chloride, agar) was used as an agar medium. However, different media may be selected, for instance, for investigating staphylococcus (a main microbe in nosocomial infections), mannite- salt-agar medium is used. For *Salmonella*, coliform bacteria, etc. involved in food poisoning, a selective agar media such as SS (*Salmonella-Shigella*) agar medium and Drigalski agar medium, and the like, may be used. In respective agar media, pH indicators such as phenol red and BTB (bromthymol blue) are contained, making it possible to know the proliferation of microbes by judging the color of medium. See Fig. 8.

Example 1. Influence of β -1.3-1.6glucan (*Aureobasidium* medium) on numbers of lymphocytes in peripheral blood

Various concentrations of β -1.3-1.6glucan (*Aureobasidium* medium) were added to the lymphocytes in healthy and normal human peripheral blood, which were cultured for 6 to 7 days at 37°C. After culture, the number of lymphocytes was counted by using hemocytometer. As a result, as shown in Fig.1, β -1.3-1.6glucan (*Aureobasidium* medium) at a fixed concentration tended to increase the number of lymphocytes in peripheral blood about 1.2 to 1.5 times compared with control group (group without β -1.3-1.6glucan).

Moreover, lymphocytes in human peripheral blood were taken out from healthy and normal person who continued to drink β -1.3-1.6glucan (*Aureobasidium* medium) for longer

than 3 years and an optimum concentration of β -1.3-1.6glucan (*Aureobasidium* medium) was added again *in vitro* to investigate the morphological change thereof. Conspicuous blast formation (image of cell division) was recognized for the group with β -1.3-1.6glucan (*Aureobasidium* medium) added, compared with the group without addition (Fig.2:

5 Photographs).

Example 2. Influence of β -1.3-1.6glucan (*Aureobasidium* medium) on production of IgG antibody

Various concentrations of β -1.3-1.6glucan (*Aureobasidium* medium) were added to the lymphocytes in healthy and normal human peripheral blood, which were cultured for 7 days at 37°C. After culture, the concentration of antibody (IgG) in the supernatant of medium was examined by enzyme antibody technique using the double antibody EIA technique. No significant effect on the production of human IgG antibody by lymphocytes in human peripheral blood was seen. This result suggests that β -1.3-1.6glucan (*Aureobasidium* medium) is unlikely to cause adverse effects, such as decreases in antibody production *in vivo*.

Table 1 Influence of β -1.3-1.6glucan (*Aureobasidium* medium) administration
IgG antibody levels.

Concentration of β -1.3-1.6glucan (mg/ml)	Concentration of IgG antibody produced (ng/ml)
0	668
7.5	835
0.75	592
0.35	663
0.18	553

Example 3. Influence of β -1.3-1.6glucan (*Aureobasidium* medium) on the production of cytokines IL-1 β or IL-2.

A fixed concentration (final concentration 400 times) of β -1.3-1.6glucan (*Aureobasidium* medium) was added to the lymphocytes in healthy and normal human peripheral blood, which was cultured for 5 days at 37°C. After culture, the concentration of cytokines (interleukin 1 : IL-1 and interleukin-2: IL-2) in the supernatant of medium was examined by enzyme antibody technique (enzyme immunoassay: EIA technique). As a result, as shown in Table 2, no remarkable difference was recognized in the level of production between the group with β -1.3-1.6 glucan (*Aureobasidium* medium) added and the group without addition. This result also suggests that the β -1.3-1.6 glucan (*Aureobasidium*) would be unlikely to cause adverse effects *in vivo*, such as effects associated with the production of IL-1 β or IL-2.

Table 2 Influence of β -1.3-1.6 glucan (*Aureobasidium* medium) on the production of cytokines

Culture	Production of cytokine	
	IL-1 β	IL-2
No addition	<10 pg/ml	< 0.8U/ml
Addition with β -1.3-1.6 glucan (<i>Aureobasidium</i> medium)	<10 pg/ml	<0.8U/ml

Example 4. Influence of β -1.3-1.6glucan (*Aureobasidium* medium) on the production of cytokine (2)

A fixed concentration (final concentration 20 times) of β -1.3-1.6glucan (*Aureobasidium* medium) was added to the monocytic model cell strain, which was cultured for 2 to 4 days at 37°C. After culture, the concentration of various cytokines (interleukin 1 β : IL-1 β , interleukin-4: IL-4, interleukin-2: IL-2, interleukin-6: IL-6 and interferon γ : IFN- γ) in the supernatant of medium was examined by enzyme antibody technique (enzyme immunoassay: EIA technique). As a result, as shown in Table 3, about 20 times or higher level of production of IL-6 was recognized for the group with β -1.3-1.6glucan (*Aureobasidium* medium) added, compared with the group without addition. However, these results suggest that administration of β -1.3-1.6 glucan would not be expected to induce side-effects associated with interleukin 1 β (IL-1 β), interleukin-4 (IL-4), interleukin-2 (IL-2), or interferon γ (IFN- γ).

Table 3 Influence of β -1.3-1.6glucan (*Aureobasidium* medium) on the production of various cytokines

Culture	Production of cytokine				
	IL-1 β	IL-2	IL-4	IL-6	IFN- γ
No addition	<10pg/ml	<0.8U/ml	<2.0pg/ml	2.0pg/ml	<0.1IU/ml
Addition with β -1.3-1.6glucan (<i>Aureobasidium</i> medium)	<10pg/ml	<0.8U/ml	<2.0pg/ml	49.5pg/ml	<0.1IU/ml

Example 5. Influence of β -1.3-1.6glucan (*Aureobasidium* medium) on normal lymphocyte cell division as measured by DNA synthesis.

β -1.3-1.6 glucan (*Aureobasidium* medium) (final concentration 400 times) was added to lymphocytes from normal and healthy human peripheral blood and also to the lymphocytes of a patient after bone marrow transplantation. The lymphocyte samples were cultured for 5 days at 37°C. After 5 days, tritiated thymidine (1 μ Ci) was added to these samples.

As shown in Table 4, normal lymphocytes treated with β -1.3-1.6glucan (*Aureobasidium* medium) exhibited increased cell division as measured by an average stimulation of DNA synthesis of about 4.5-times, compared to untreated normal lymphocytes.

Table 5 shows that lymphocytes from a majority of bone marrow transplantation patients also showed stimulation of cell division as measured by DNA synthesis. The stimulation index in Tables 4 and 5 represents the ratio of counts (cpm) in lymphocyte samples that were treated with β -1.3-1.6glucan (*Aureobasidium* medium) over untreated controls.

Table 4 Influence of β -1.3-1.6glucan (*Aureobasidium* medium) on cell division as measured by DNA synthesis in lymphocytes from healthy and normal subjects.

Lymphocyte in peripheral blood	Capability of DNA synthesis (cpm)		SI (Stimulation index)
	No addition	Addition with β -1.3-1.6glucan (<i>Aureobasidium</i> medium)	
SA	624	851	1.4
TS	444	2067	4.7
YA	460	1232	2.7
IS	238	2177	9.1

cpm: Count per minute

SI: Stimulation Index

Table 5 Influence of β -1.3-1.6glucan (*Aureobasidium* medium) on cell division as measured by DNA synthesis in patients after bone marrow transplantation.

Lymphocyte	Transplantation form	Capability of DNA synthesis stimulation index (SI)	
		Stimulation with β -1.3-1.6glucan (<i>Aureobasidium</i> medium)	
		Primary Stimulation	Secondary Stimulation
SU	Patient with bone marrow transplantation (Allogenic bone marrow transplantation)	2.7	2.7
AI	Patient with bone marrow transplantation (Allogenic bone marrow transplantation)	3.6	5.2
KM	Patient with bone marrow transplantation (Allogenic bone marrow transplantation)	3.6	2.1
NO	Patient with bone marrow transplantation (Autologous bone marrow transplantation)	2.3	2.7
TM	Patient with bone marrow transplantation (Allogenic bone marrow transplantation)	1.2	0.6
ZT	Patient with bone marrow transplantation (Autologous bone marrow transplantation)	2.0	2.2
YK	Patient with cord marrow transplantation (Allogenic transplantation)	1.0	1.3
SF	Patient with cord marrow transplantation (Allogenic transplantation)	1.2	0.9

Example 6. Influence of β -1.3-1.6glucan (*Aureobasidium* medium) on the proliferation of cancer cells

β -1.3-1.6Glucan (*Aureobasidium* medium) (final concentration 20 times) was added to various leukemia cells, which were cultured for 1 to 3 days at 37°C. After culture, the number of leukemia cells was counted by using hemocytometer to investigate the influence on the proliferation of leukemia cell. As shown in Figs 3-6, addition of β -1.3-1.6glucan (*Aureobasidium* medium) directly inhibited the proliferation of cancer (leukemia) cells. These data suggest the direct killing of cancer (leukemia) cells, for instance, by induction of programmed death (apoptosis), as other components of the immune system were absent.

Example 7. Influence of β -1.3-1.6glucan (*Aureobasidium* medium) on the dynamics of cell surface molecule (receptor molecule) in monocyte/macrophage model system

β -1.3-1.6Glucan (*Aureobasidium* medium) (final concentration 20 times) was added to the cells in a monocyte/macrophage model system. Cells were cultured for 24 hours at 37°C. After 24 hours, the cells were collected and the dynamics of various human cell membrane antigens (receptor: CD antigen) were analyzed by indirect fluorescence antibody technique (flow cytophotometry technique) that uses various monoclonal antibodies. As shown in Fig.7, the levels of CD11a and CD49d molecules on the surface of cells in monocyte/macrophage model system cultured with β -1.3-1.6glucan (*Aureobasidium* medium) were down-regulated.

Example 8. Effect of β -1.3-1.6glucan (*Aureobasidium* medium) on the prevention of propagation (proliferation) of environmental microbes

The removal or inactivation of environmental microbes adhered to surfaces or organisms is an important subject in the fields of medical care, health and welfare. Such removal or inactivation is particularly important for the prevention of nosocomial infections. Therefore, the antimicrobial effects of β -1.3-1.6glucan (*Aureobasidium* medium) on the proliferation of environmental microbes adhered to hands, feet and body, was evaluated using a palm stamp technique involving contacting the palm of the hand with a solid microbial medium. The hands of control subjects were contacted to the medium for about 20 seconds.

The hands of those in the experimental group were first wiped with a solution containing β -1.3-1.6glucan (*Aureobasidium* medium) and dried for about 5 minutes prior to contact with the medium. Similarly to the control group, the hands were then contacted with the nutritional solid medium for about 20 seconds.

5 The solid medium was cultured for 1 to 2 days at room temperature, and the proliferation of microbes (number of colonies) was observed. As shown in Fig. 8, the palm stamps of hands treated with β -1.3-1.6glucan (*Aureobasidium* medium) showed far fewer microbial contaminants. This shows that the β -1.3-1.6glucan (*Aureobasidium* medium) inhibits the proliferation of environmental microbes and can be used as a sanitizer or the
10 bodies of persons who are aged or infirm and cannot bathe and also for the prevention of nosocomial infections and removal of environmental pollutants.

Modifications and other embodiments

Various modifications and variations of the described glucan products, compositions and methods as well as the concept of the invention will be apparent to those skilled in the art without departing from the scope and spirit of the invention. Although the invention has
15 been described in connection with specific preferred embodiments, it should be understood that the invention as claimed is not intended to be limited to such specific embodiments. Various modifications of the described modes for carrying out the invention which are obvious to those skilled in the chemical, biological, medical, environmental, cosmetic or food
20 arts or related fields are intended to be within the scope of the following claims.

Incorporation by Reference

Each document, patent application or patent publication cited by or referred to in this disclosure is incorporated by reference in its entirety. Any patent document to which this application claims priority is also incorporated by reference in its entirety. Specifically,
25 priority documents Japanese Patent Application 2000-342310, filed November 9, 2000, is hereby incorporated by reference.